Treatment strategies for hypertension in patients with type 1 diabetes

References

• Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.
   PubMed Web of Science ®Google Scholar
• Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Prim. 2017;3:17016.
   PubMed Web of Science ®Google Scholar
• Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013;13:814–823.
   PubMed Web of Science ®Google Scholar
• Willi SM, Miller KM, DiMeglio LA, et al. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015;135:424–434.
   PubMed Web of Science ®Google Scholar
• Diaz-Valencia PA, Bougnères P, Valleron A-J. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health. 2015;15:255.
   PubMed Web of Science ®Google Scholar
• Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376:1419–1429.
   PubMed Web of Science ®Google Scholar
• Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014:371:1972–1982.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Wallin A, Håkansson N, et al. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol. 2018;262:66–70.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and. Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) research group. Risk factors for cardiovascular disease in type 1 diabetes. Diabetes. 2016;65:1370–1379.
   PubMedGoogle Scholar
• Mühlhauser I, Overmann H, Bender R, et al. Predictors of mortality and end-stage diabetic complications in patients with Type 1 diabetes mellitus on intensified insulin therapy. Diabet Med. 2000;17:727–734.
   PubMed Web of Science ®Google Scholar
• Gallego PH, Craig ME, Hing S, et al. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ. 2008;337:a918.
   PubMedGoogle Scholar
• Raile K, Galler A, Hofer S, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30:2523–2528.
   PubMed Web of Science ®Google Scholar
• Groop P-H, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58:1651–1658.
   PubMed Web of Science ®Google Scholar
• Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496–501.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169:1307–1316.
   PubMed Web of Science ®Google Scholar
• Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the pittsburgh epidemiology of diabetes complications study experience. Diabetes. 2006;55:1463–1469.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2017;2018(71):1269–1324.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;2018(39):3021–3104.
   Web of Science ®Google Scholar
• Collado-Mesa F, Colhoun HM, Stevens LK, et al. Prevalence and management of hypertension in Type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet Med. 1999;16:41–48.
   PubMed Web of Science ®Google Scholar
• Maahs DM, Kinney GL, Wadwa P, et al. Hypertension Prevalence, Awareness, Treatment, and Control in an Adult Type 1 Diabetes Population and a Comparable General Population. Diabetes Care. 2005;28:301–306.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Kestenbaum B, Rue TC, et al. Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. JAMA Intern Med. 2008;168:1867–1873.
   Google Scholar
• Ahmadizar F, Souverein P, de Boer A, et al. Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. Br J Clin Pharmacol. 2018;84:776–785.
   PubMed Web of Science ®Google Scholar
• Bain SC, Gill GV, Dyer PH, et al. Characteristics of Type 1 diabetes of over 50 years duration (the golden years cohort). Diabet Med. 2003;20:808–811.
   PubMed Web of Science ®Google Scholar
• Bhattarai S, Godsland IF, Misra S, et al. Metabolic health and vascular complications in type 1 diabetes. J Diabetes Complications. 2019;33:634–640.
   PubMed Web of Science ®Google Scholar
• Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: scottish registry linkage study. PLOS Med. 2012;9:e1001321.
   PubMed Web of Science ®Google Scholar
• Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510–2516.
   PubMed Web of Science ®Google Scholar
• McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:771–776.
   PubMed Web of Science ®Google Scholar
• Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res. 2013;10:472–482.
   PubMed Web of Science ®Google Scholar
• Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care. 2003;26:1589–1596.
   PubMed Web of Science ®Google Scholar
• Fiorentino TV, Prioletta A, Zuo P, et al. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19:5695–5703.
   PubMed Web of Science ®Google Scholar
• Bagi Z, Feher A, Cassuto J, et al. Increased availability of angiotensin AT1 receptors leads to sustained arterial constriction to angiotensin II in diabetes – role for Rho-kinase activation. Br J Pharmacol. 2011;163:1059–1068.
   PubMed Web of Science ®Google Scholar
• Sochett E, Noone D, Grattan M, et al. Relationship between serum inflammatory markers and vascular function in a cohort of adolescents with type 1 diabetes. Cytokine. 2017;99:233–239.
   PubMed Web of Science ®Google Scholar
• Ayad F, Belhadj M, Pariés J, et al. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med. 2010;27:804–811.
   PubMed Web of Science ®Google Scholar
• Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48:164–171.
   PubMed Web of Science ®Google Scholar
• Brook RD, Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens. 2000;13:112S–122S.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Grignolo A, Kuhn CM, et al. Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats. Life Sci. 1983;33:169–180.
   PubMed Web of Science ®Google Scholar
• Distiller LA. Why do some patients with type 1 diabetes live so long? World J Diabetes. 2014;5:282–287.
   PubMedGoogle Scholar
• Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601–610.
   PubMed Web of Science ®Google Scholar
• Benhamou PY, Halimi S, De Gaudemaris R, et al. Early disturbances of ambulatory blood pressure load in normotensive type i diabetic patients with microalbuminuria. Diabetes Care. 1992;15:1614–1619.
   PubMed Web of Science ®Google Scholar
• Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2015;22:277–282.
   PubMedGoogle Scholar
• Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the obesity society and the american society of hypertension. J Clin Hypertens. 2013;15:14–33.
   PubMed Web of Science ®Google Scholar
• Kotsis V, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386–393.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis. Lancet. 2016;387:957–967.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: A report from an ADA consensus conference. Diabetes Care 2014;37: 2864–2883.
   PubMed Web of Science ®Google Scholar
• De Ferranti SD, De Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease a scientific statement from the american heart association and american diabetes association. Circulation. 2014;130:1110–1130.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;2020(41):255–323.
   Google Scholar
• de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the american diabetes association. Diabetes Care. 2017;40:1273–1284.
   PubMed Web of Science ®Google Scholar
• Stergiou G, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: international database of home blood pressure in relation to cardiovascular outcome. Hypertension. 2014;63:675–682.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;2016(37):2315–2381.
   Web of Science ®Google Scholar
• Volpe M, Battistoni A, Tocci G, et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens. 2012;30:1056–1064.
   PubMed Web of Science ®Google Scholar
• Giannopoulou EZ, Doundoulakis I, Antza C, et al. Subclinical arterial damage in children and adolescents with type 1 diabetes: A systematic review and meta-analysis. Pediatr Diabetes. 2019;20:668–677.
   PubMed Web of Science ®Google Scholar
• Emdin C, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes a systematic review and meta-analysis. JAMA. 2015;313:603–615.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2296–2304.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613–622.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–944.
   PubMed Web of Science ®Google Scholar
• Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799–2810.
   PubMed Web of Science ®Google Scholar
• Günther A, Liese AD, Bell RA, et al. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. Hypertension. 2009;53:6–12.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861–866.
   PubMed Web of Science ®Google Scholar
• Beretta MV, Bernaud FR, Nascimento C, et al. Higher fiber intake is associated with lower blood pressure levels in patients with type 1 diabetes. Arch Endocrinol Metab. 2018;62:47–54.
   PubMed Web of Science ®Google Scholar
• Altorf-van der Kuil W, Engberink MF, IJpma I, et al. Protein intake in relation to risk of hypertension and microalbuminuria in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. J Hypertens. 2013;31:1151–1159.
   PubMed Web of Science ®Google Scholar
• Toeller M, Buyken A, Heitkamp G, et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia. 1997;40:1219–1226.
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressureresults from the DCCT. JAMA. 1998;280:140–146.
   PubMed Web of Science ®Google Scholar
• Bohn B, Herbst A, Pfeifer M, et al. Impact of physical activity on glycemic control and prevalence of cardiovascular risk factors in adults with type 1 diabetes: a cross-sectional multicenter study of 18,028 patients. Diabetes Care. 2015;38:1536–1543.
   PubMed Web of Science ®Google Scholar
• Appel L, Champagne C, Harsha D, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–2093.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association.10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S103–S123.
   PubMed Web of Science ®Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–1903.
   PubMed Web of Science ®Google Scholar
• Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.
   PubMedGoogle Scholar
• Ahmad J, Shafique S, Abidi SMA, et al. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract. 2003;60:131–138.
   PubMed Web of Science ®Google Scholar
• Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890–899.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.
   PubMed Web of Science ®Google Scholar
• Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51.
   PubMed Web of Science ®Google Scholar
• Maahs DM, Snell-Bergeon JK, Kinney GL, et al. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complications. 2007;21:273–279.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting–enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S90–S102.
   PubMed Web of Science ®Google Scholar
• Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9:48–53.
   PubMed Web of Science ®Google Scholar
• Sanidas EA, Papadopoulos DP, Hatziagelaki E, et al. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension. Am J Hypertens. 2019 September 21. Epub ahead of print. DOI:10.1093/ajh/hpz157.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019;365:I1328.
   PubMedGoogle Scholar
• Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41:2552–2559.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41:2560–2569.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events. Circulation. 2018;137:323–334.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
   PubMed Web of Science ®Google Scholar
• Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34:208–230.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Manafis A, Mitas C, et al. Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice. Cardiovasc Haematol Disord Drug Targets. 2018;18:139–146.
   PubMedGoogle Scholar
• Taylor SI, Blau JE, Rother KI, et al. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019. Epub ahead of print. DOI:10.1016/S2213-8587(19)30154-8.
   Web of Science ®Google Scholar
• Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with Sodium–Glucose Cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42:1147–1154.
   PubMed Web of Science ®Google Scholar
• Patoulias D, Doumas M, Kotsis V, et al. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis. Curr Diabetes Rev. 2019. Epub ahead of print. DOI:10.2174/1573399815666190614141918.
   PubMed Web of Science ®Google Scholar
• Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4:221–232.
   PubMed Web of Science ®Google Scholar
• Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes : a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 2016;39:1027–1035.
   PubMed Web of Science ®Google Scholar
• Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840.
   PubMed Web of Science ®Google Scholar